What's the impact of antacids on tigecycline's absorption?

How do antacids affect tigecycline absorption?

Tigecycline absorption can be reduced when it is taken with antacid medicines, because antacids increase gastric pH and can interfere with tigecycline’s dissolution and absorption in the stomach and upper intestine. This can lead to lower systemic exposure after an oral course is used (though tigecycline itself is administered intravenously in clinical practice, so “oral absorption” concerns are mainly relevant to any oral formulation or when tigecycline is discussed in the context of drug–food/pH interactions) [1].

What mechanism explains the interaction?

Most antacids act by neutralizing stomach acid, raising gastric pH. Changes in pH can alter how well a drug dissolves before it is absorbed, which can lower bioavailability for pH-sensitive compounds. Antacids are a classic pH-changing interaction route that can reduce exposure of certain medications [1].

How long does the effect last after taking antacids?

The interaction is driven by the temporary change in stomach acidity after antacid dosing. So the reduction in drug exposure is generally expected during the period when the antacid is actively elevating gastric pH (timing depends on the specific antacid formulation and dosing schedule) [1].

Does it matter which antacid you take (calcium carbonate vs. others)?

The clinically relevant factor is the antacid’s effect on gastric pH rather than the specific active ingredient. Different antacids can produce different degrees and durations of pH elevation, but the direction of the effect on pH-dependent absorption risk is the same [1].

What should patients do to avoid the interaction?

If you are comparing tigecycline taken alongside antacid medicines, the practical approach is timing separation when feasible and following the prescribing information or clinician instructions for your specific regimen. Because tigecycline is typically not taken orally, the “absorption” interaction is most relevant when a drug is formulated or studied for oral use, or when another medication schedule involves pH-changing antacids that could affect exposure of co-administered agents [1].

Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm